YNHH Clinical Trials for Hospitalized Patients with Confirmed COVID-19

Disclaimer: There are no FDA-approved treatments for COVID-19, supportive care is standard of care. Limited treatment data are available & clinical judgment is warranted - Algorithm last updated 3/31/20

Oxygen supplementation

Yes

Number of days from symptom onset to presentation

> 5 days

Remdesivir moderate disease Clinical Trial

≤ 5 days

Consider sarilumab trial.

Inclusion criteria for sarilumab:
1) Pneumonia (clinical or radiographic) **PLUS**
2) Oxygen requirement OR need for vasopressor, ECMO or RRT OR Immunocompromised

* Exclusion criteria for sarilumab:
- Unlikely to survive >48 hours from screening
- ANC <2000 mm³
- ALT/AST >5x ULN
- Platelets <50 000
- Treatment with anti-IL6 agents or Janus kinase inhibitors within 30 days
- Current treatment with DMARDs
- Chronic steroids ≥ prednisone 10 mg or equivalent
- History of current autoimmune or inflammatory disease except RA
- Suspected active infection (bacterial, fungal) or incompletely treated TB
- Immunosuppressive antibody therapy within 5 months including IVIG
- Participation in another clinical trial within 3 months or 5 half-lives of drug

If patient excluded* and onset >5 days prior, would consider YNHH treatment protocol instead.

Consider remdesivir severe trial.

Inclusion criteria for remdesivir:
- Age >12
- Infiltrate on imaging
- Positive SARS CoV-2 PCR within last 4 days

Δ Exclusion criteria for remdesivir:
- eGFR <50
- Pregnancy
- ALT or AST >5x ULN
- Participation in another trial
- Mechanically ventilated > 5 days

If patient excluded Δ, evaluate for sarilumab trial even if ≤ 5 days.

Remdesivir Trial: Contact Laurie Andrews at 203-785-3557 for eligibility/enrollment
PI: Dr. Onyema Ogbuagu

Clinical trial enrollment and status change rapid. Contact study coordinators for latest information.

Sirolumab Trial: Contact Nicole Grant at 203-737-4818 for eligibility/enrollment
PI: Dr. Geoffrey Chupp